FK506 reduces abnormal prion protein through the activation of autolysosomal degradation and prolongs survival in prion-infected mice
スポンサーリンク
概要
- 論文の詳細を見る
Prion diseases are fatal neurodegenerative disorders and no effective treatment has been established to date. In this study, we evaluated the effect of FK506 (tacrolimus), a macrolide that is known to be a mild immunosuppressant, on prion infection, using cell culture and animal models. We found that FK506 markedly reduced the abnormal form of prion protein (PRNPSc) in the cell cultures (N2a58 and MG20) infected with Fukuoka-1 prion. The levels of autophagy-related molecules such as LC3-II , ATG12-ATG5 and ATG7 were significantly increased in the FK506-treated cells, and resulted in the increased formation of autolysosomes. Upregulation of the autophagy-related molecules was also seen in the brains of FK506-treated mice and the accumulation of PRNPSc was delayed. The survival periods in mice inoculated with Fukuoka-1 were significantly increased when FK506 was administered from day 20 post-inoculation. These findings provide evidence that FK506 could constitute a novel antiprion drug, capable of enhancing the degradation of PRNPSc in addition to attenuation of microgliosis and neuroprotection.
- Landes Bioscienceの論文
- 2013-09-00
Landes Bioscience | 論文
- Photosynthesis-dependent Ca2+influx and functional diversity between phospholipases in the formation of cell polarity in migrating cells of red algae
- Effects of cell wall synthesis on cell polarity in the red alga Porphyra yezoensis
- Suppressive Effect of Modified Dominant Negative RAS Mutant on Human Cancer by Gene Transfer with Non-Viral Vector
- Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small cell lung cancer
- Protective role of MyD88-independent innate immune responses against prion infection